FSH

Juno Health Showcasing Better EHR User Experiences Through Personalization at HIMSS24

Retrieved on: 
Tuesday, February 13, 2024
Collection, IPad Pro, Mental health, HIMSS, Health, Bed, EHR, Food, Conference, Health care, Drink, DCF, Apple, Patient safety, Florida State Hospital, Florida Department, FSH, Electronic health record

JUNO BEACH, Fla., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Juno Health, a leader in healthcare innovation and digital transformation, will be showcasing a wide-range of key innovations that enhance the user experience through personalization within its Juno EHR solutions at the upcoming HIMSS24 Global Health Conference in Orlando, Florida.

Key Points: 
  • See It in Action at HIMSS 2024, Booth # 1161
    JUNO BEACH, Fla., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Juno Health , a leader in healthcare innovation and digital transformation, will be showcasing a wide-range of key innovations that enhance the user experience through personalization within its Juno EHR solutions at the upcoming HIMSS24 Global Health Conference in Orlando, Florida.
  • Today's care organizations require an EHR that can be personalized to work how clinicians work, without outside vendor involvement.
  • By implementing Juno EHR for Behavioral Health , DCF is leveraging an EHR that is a browser-based, cloud native solution that can support their mission now and in the future.
  • This includes the Flamingle reception at the Juno Health booth on March 13 from 4:30 to 6 p.m. as part of the HIMSS24 Exhibit Social Hour.

Gabrielle Union Joins Clearblue® in Latest Campaign to Turn Up the Volume on Menopause

Retrieved on: 
Thursday, November 9, 2023
Other Health, General Health, Entertainment, Social Media, Consumer, Apps, Applications, Technology, Celebrity, Biotechnology, Women, Communications, Medical Supplies, Health, FSH, Woman, Urine, Fertility, Union, Menopause, Clearblue, Multimedia, MD, Partnership, R, Doctor of Philosophy, MSCP, Birth control

Clearblue®, the world’s #1 selling brand in home pregnancy and fertility tests1, has teamed up with actress Gabrielle Union, an active advocate for women’s health, to turn up the volume on the menopause conversation.

Key Points: 
  • Clearblue®, the world’s #1 selling brand in home pregnancy and fertility tests1, has teamed up with actress Gabrielle Union, an active advocate for women’s health, to turn up the volume on the menopause conversation.
  • View the full release here: https://www.businesswire.com/news/home/20231109375918/en/
    Gabrielle Union teams up with Clearblue to continue turning up the volume on menopause conversations.
  • (Photo: Business Wire)
    “I’m so proud to partner with Clearblue® and join their mission to help women feel educated and empowered as they take on perimenopause and menopause,” said Union.
  • “Menopause is a subject we still often ignore, and it leaves women feeling confused, silenced and completely unprepared.

Florida Department of Children and Families Chooses Juno EHR from Juno Health

Retrieved on: 
Thursday, November 16, 2023
Cloud, FSH, EHR, Safety, Florida Department, Patient safety, Software, Commercial Operating System, ONC, DCF, Collection, Bed, Mental health, DSS, Software as a service, 21st Century Cures Act, Environment, Florida State Hospital, Nursing, Management, Service

JUNO BEACH, Fla., Nov. 16, 2023 /PRNewswire-PRWeb/ -- Juno Health, the commercial division of DSS, Inc., has announced that the Florida Department of Children and Families (DCF) has chosen Juno EHR as its electronic health record (EHR) for Florida State Hospital (FSH) in Chattahoochee, FL. DCF's stated vision for this implementation is to improve the delivery of care, improve collection and availability of clinical information, increase patient safety, and improve patient outcomes.

Key Points: 
  • JUNO BEACH, Fla., Nov. 16, 2023 /PRNewswire-PRWeb/ -- Juno Health , the commercial division of DSS, Inc., has announced that the Florida Department of Children and Families ( DCF ) has chosen Juno EHR as its electronic health record (EHR) for Florida State Hospital (FSH) in Chattahoochee, FL.
  • "We are excited that the DCF has chosen Juno EHR to advance its behavioral health capabilities through the use of a highly flexible and configurable EHR solution," said J. Michael Fehr, Vice President, Commercial Operations at Juno Health.
  • By implementing Juno EHR for Behavioral Health , Florida DCF is leveraging an EHR that is a browser based, cloud native solution that can support their mission now and in the future.
  • "We are excited that the DCF has chosen Juno EHR to advance its behavioral health capabilities through the use of a highly flexible and configurable EHR solution," said J. Michael Fehr, Vice President, Commercial Operations at Juno Health.

Reproductive Endocrinologist Dr. Bana Kashani Shares Advice for Women Trying to Conceive with PCOS during PCOS Awareness Month

Retrieved on: 
Tuesday, September 19, 2023
Women, Baby, Maternity, Convenience Store, Practice Management, General Health, Consumer, Health, Retail, Science, Other Science, Yoga, Medicine, Insulin, Ovulation, Pregnancy, Senior counsel, Woman, Infertility, Research, Obesity, Polycystic ovary syndrome, FSH, Hormone, CDC, Patient, PCOS, Korea Disease Control and Prevention Agency, Fertility, Meditation, Human, Birth control

According to the Centers for Disease Control and Prevention (CDC), one in ten women in their childbearing years have PCOS; however, 70% of cases are undiagnosed.

Key Points: 
  • According to the Centers for Disease Control and Prevention (CDC), one in ten women in their childbearing years have PCOS; however, 70% of cases are undiagnosed.
  • In light of PCOS Awareness Month, Banafsheh Kashani , M.D., OB-GYN, reproductive endocrinologist and infertility specialist, is sharing her top tips for women trying to conceive with PCOS.
  • “Conceiving with PCOS can be a complex and emotional journey for the millions of women affected,” says Dr. Kashani.
  • However, research shows that losing just 5-10% of body weight can significantly improve fertility in women with PCOS.

Clearblue® Launches First Ever At-Home Product That Can Indicate a Woman’s Current Stage of Menopause¹

Retrieved on: 
Tuesday, August 29, 2023
Family, Retail, Consumer, Other Retail, Women, Specialty, Pregnancy, Urine, Menopause, Woman, Multimedia, Doctor of Philosophy, FSH, MS, MSCP, Clearblue, Fertility, Diagnosis, R, Birth control, Medical device, MD

“I am thrilled to be teaming up with Clearblue® for the launch of their Menopause Stage Indicator.

Key Points: 
  • “I am thrilled to be teaming up with Clearblue® for the launch of their Menopause Stage Indicator.
  • It is a groundbreaking product that will be beneficial for both women and healthcare professionals,” said menopause expert, Dr. Heather Hirsch, MD, MS, MSCP.
  • The Clearblue® Menopause Stage Indicator is a game-changer that will help empower women with information and understanding of their menopause journey.”
    The Clearblue® Menopause Stage Indicator will be available for purchase at retailers across the United States.
  • More information can be found at https://clearblue.com/menopause/stage-indicator , or by following along on social with the hashtag #MenoStage or @clearblue on Instagram.

The Worldwide At-Home Diagnostic Testing Market to 2027 - Surging Demand for Early Disease Diagnosis, Personalized Medicine & Expanded Technologies Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
Biotechnology, Health, Medical Devices, TSH, Pregnancy, HIV, Marketing, Glucose, Cholesterol, Ovulation, Power-on self-test, Cancer, Research, DSM-IV codes, Supermarket, FSH, Internet, GINA, Home, Patient, OTC, Genetic testing, IVD, Growth, Diagnosis, Genetic Information Nondiscrimination Act, Family, Allergen, Pharmaceutical industry, Medical imaging, Vaccine

Outside the United States, consumers will find OTC tests for a wider range of analytes including allergens, TSH, and FSH.

Key Points: 
  • Outside the United States, consumers will find OTC tests for a wider range of analytes including allergens, TSH, and FSH.
  • The forecasted market analysis for 2022-2027 was largely based on demographic trends, new developments, innovative technology and global expansion.
  • Drivers include the growing demand for early disease detection and diagnosis, personalized medicine, the importance of disease monitoring, expanded technologies and cost.
  • Several trends are continuing to shape the home laboratory testing market including the growing demand for early disease detection and diagnosis, personalized medicine, the importance of disease monitoring, expanded technologies and cost.

Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

Retrieved on: 
Tuesday, June 27, 2023
Research, Women, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Science, Other Science, Injection, Male, Inc., Pregnancy, FSHR, Drug development, ESHRE, Ovulation, Woman, Infertility, Polycystic ovary syndrome, Life expectancy, Solubility, Drug design, IVF, FSH, CDC, Protein, GPCR, Publication, PCOS, Fertility, Human Reproduction (journal), European Society of Gynaecological Oncology, AMHR2, Reproductive endocrinology and infertility, TSHR, Egg, Pharmaceutical industry, Birth control, Embryology

Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.

Key Points: 
  • Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.
  • Therefore, a successful oral FSHR drug must stimulate the FSH receptor without stimulating the thyroid hormone receptor (TSHR).
  • Early Celmatix data suggests that their unique, rationally designed compounds overcome this significant hurdle to drug development for this target.
  • Celmatix Chief Scientific Officer, Dr. Stephen Palmer, notes, “We are very pleased to see that several of our novel compounds demonstrate the desired potency and selectivity required for a successful oral FSH drug.

Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Retrieved on: 
Tuesday, June 20, 2023
Science, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Other Health, Hodgkin lymphoma, Doxorubicin, Inc., Vincristine, Brentuximab vedotin, Vinblastine, PML, Takeda, Progression-free survival, Hematology, ABVD, ICML, Procarbazine, Survival, Lymphoma, PET, Cyclophosphamide, Bleomycin, ADCETRIS, CHL, PFS, Teaching hospital, Dexamethasone, FSH, Research and development, Dacarbazine, Prednisone, Development, Etoposide, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Risk, Progressive multifocal leukoencephalopathy, Fertility, BEACOPP, Peripheral neuropathy, Death, Society, Conference, Pharmaceutical industry, Birth control, Seagen

The data results of the HD21 study were presented in a late-breaking session at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 17.

Key Points: 
  • The data results of the HD21 study were presented in a late-breaking session at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 17.
  • 12-month post-treatment safety data were consistent with previously presented HD21 data results at the American Society of Hematology 2022 Annual Meeting.
  • Preservation of fertility potential was indicated by measurement of follicle-stimulating hormone (FSH) and was available for 597 patients.
  • Please see Important Safety Information, including a BOXED WARNING for progressive multifocal leukoencephalopathy (PML), for ADCETRIS below.

Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics Sales Analysis Report 2023: 71 Biologic Therapeutics Reached Blockbuster Status with 2022 Sales Exceeding $ 1 Billion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, Health, Oncology, FSH, Antibody, Growth hormone, Small RNA, Biosimilar, G-CSF, US, Publication, Therapy, Recombinant, RNA, Vaccine, Fine chemical, Protein

The "2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2022.
  • Publicly available 2022 sales data of biosimilar antibodies and proteins are included in the report provided from the companies.
  • A total of 71 biologic therapeutics reached blockbuster status with 2022 sales exceeding US$ 1 bln.

Idaho Talent Fest puts out open call for performers to take part in this annual benefit event for FSHD Muscular Dystrophy

Retrieved on: 
Thursday, February 2, 2023
Online, PC, Audition, Web Cartoonists' Choice Awards, Disability, People's Choice Awards, Pain, Radio, FSH, Muscular dystrophy, Research, Family, FSHD, Bulgaria in the Junior Eurovision Song Contest 2015, Disease, Boise, Idaho, Volunteering, Facioscapulohumeral muscular dystrophy, Maastricht University Special Collections, Pharmaceutical industry

BOISE, Idaho, Feb. 2, 2023 /PRNewswire-PRWeb/ -- In 2021, volunteer leaders of the Idaho Chapter of the FSHD Society spearheaded a creative way to engage Idaho residents in their goal to fund crucial research to treat fascioscapulohumeral muscular dystrophy (FSH muscular dystrophy or FSHD), a rare disease that directly impacts their family when they launched the Idaho Talent Fest.

Key Points: 
  • This 3rd annual talent competition is open to all interested performers.
  • The live event will spotlight and celebrate many talented area residents while raising funds and awareness for those suffering from FSH Muscular Dystrophy.
  • The FSHD Society is the world's largest research-focused patient organization for facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy.
  • For more information about this event, the audition process, or FSHD, please contact Minette Hale at 208.608.2418 or [email protected]